NLS Pharma

38 articles with NLS Pharma

• NLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Direct Offering

  4/26/2022

  NLS Pharmaceutics Ltd. announced the closing of its previously announced registered direct offering with health-care focused institutional investors alongside participation from the Company's Chairman of the Board of Directors, Ronald Hafner, for the purchase and sale of 4,200,000 of the Company's common shares at a purchase price of $1.04 per common share.

• NLS Pharmaceutics to Participate in the B. Riley Annual Neuro & Ophthalmology Investor Conference

  4/22/2022

  NLS Pharmaceutics Ltd. announces that Alex Zwyer, CEO and Co-Founder, will participate in a fireside chat at the B. Riley Annual Neuro & Ophthalmology Investor Conference being held April 27-28, 2022.

• NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

  4/13/2022

  NLS Pharmaceutics Ltd. today announced that it has entered into definitive agreements with health-care focused institutional investors alongside participation from the Company's Chairman f the Board of Directors, Ronald Hafner, for the purchase and sale of 4,200,000 of the Company's common shares.

• NLS Pharmaceutics Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements

  4/1/2022

  NLS Pharmaceutics Ltd. announces that it has received a letter from the Listing Qualifications staff of The Nasdaq Stock Market notifying the Company that it is no longer in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market.

• NLS Pharmaceutics Retains LifeSci Partners As Financial Advisor To Evaluate Strategic Partnering Initiatives

  3/31/2022

  NLS Pharmaceutics Ltd. announces that it has retained LifeSci Partners as financial advisor to assist the Company in evaluating a variety of strategic partnering initiatives.

• NLS Pharmaceutics Announces Early Access Program (EAP) Allowing Patients with Idiopathic Hypersomnia to Receive Treatment with Mazindol ER

  3/28/2022

  NLS Pharmaceutics Ltd. announces that it has entered into an agreement with Caligor Coghlan Pharma Services (CCPS) to administer a Named Patient Program enabling European patients with Idiopathic Hypersomnia (IH) to have pre-approval access to treatment with the Company's novel Mazindol ER formulation.

• 

  Long COVID: New Insights Could Provide Treatment Options

  3/28/2022

  Although some may be hopeful that the end of the COVID-19 pandemic is nearby, millions still are facing their own lifelong version of the pandemic.

• NLS Pharmaceutics to Participate in Maxim Group 2022 Virtual Growth Conference

  3/25/2022

  NLS Pharmaceutics Ltd announces that Alex Zwyer, CEO and Co-Founder, will participate in a fireside chat at the Maxim Group 2022 Virtual Growth Conference, being held March 28-30, 2022.

• NLS Pharmaceutics Announces Positive Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy

  3/16/2022

  NLS Pharmaceutics Ltd. announces positive interim top-line data from its Phase 2a clinical trial evaluating its lead product candidate, Quilience® (Mazindol ER), in the treatment of narcolepsy.

• NLS Pharmaceutics to Participate in the SACHS 15th Annual European Life Sciences Virtual CEO Forum and a Fireside Chat with Maxim Analyst in March

  2/25/2022

  NLS Pharmaceutics Ltd. announces that Alex Zwyer, Chief Executive Officer and Co-Founder, will be available for one-on-one meetings with conference attendees at the SACHS 15th Annual European Life Sciences Virtual CEO Forum taking place March 1-2, 2022.

• NLS Pharmaceutics to Present Interim Top-Line Data for Quilience(R) (Mazindol ER) in Patients with Narcolepsy at the World Sleep Congress in March 2022

  2/7/2022

  NLS Pharmaceutics Ltd. announces that it will present interim top-line data from its Phase 2a clinical trial evaluating its lead product candidate, Quilience.

• NLS Pharmaceutics Announces Patent Issuance in the United States for its Mazindol Extended-Release Formulation

  1/4/2022

  NLS Pharmaceutics Ltd. announces that the United States Patent and Trademark Office has granted the Company U.S. Patent No. 11207271, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER.

• NLS Pharmaceutics CEO Issues Letter to Shareholders

  11/1/2021

  NLS Pharmaceutics Ltd. announces that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders

• NLS Pharmaceutics Announces Preclinical Data Demonstrating the Potential of NLS-4 (Lauflumide) to Treat Chronic Fatigue Associated With Long-COVID

  10/14/2021

  NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces preclinical data for NLS-4, the Company's next-generation wake-promoting drug candidate, which has shown promise for the treatment of chronic fatigue associated with Long-COVID.

• NLS Pharmaceutics to Participate in The Micro Cap Rodeo Fall Harvest Conference: Best Ideas from the Buy-side

  9/30/2021

  NLS Pharmaceutics Ltd. announces that its Chief Executive Officer and Co-Founder Alex Zwyer is scheduled to present a corporate overview and meet with investors at The Micro Cap Rodeo Fall Harvest Conference to be held virtually October 5-8, 2021.

• NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment

  9/28/2021

  NLS Pharmaceutics Ltd. today announced that it has entered into a standby equity distribution agreement, or SEDA, with YA II PN, Ltd.

• NLS Pharmaceutics to Participate in the Benzinga Healthcare Small Cap Conference

  9/24/2021

  NLS Pharmaceutics Ltd. announces that its Chief Executive Officer and Co-Founder Alex Zwyer is scheduled to participate in a live interview and meet with investors at the Benzinga Healthcare Small Cap Conference on September 29-30, 2021.

• NLS Initiates Phase 2 Trial for Quilience in Narcolepsy and Announces First Patient Enrolled

  9/14/2021

  NLS Pharmaceutics Ltd. announces the initiation of its Phase 2 clinical trial evaluating Quilience® as a once-daily monotherapy for the treatment of excessive daytime sleepiness and cataplexy, the primary symptoms of narcolepsy.

• NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference

  9/8/2021

  NLS Pharmaceutics Ltd. announces that Alex Zwyer, Chief Executive Officer and Co-Founder, is scheduled to present a corporate overview and participate in meetings with investors at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021.

• NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Application Covering its Proprietary Mazindol Formulation

  8/19/2021

  NLS Pharmaceutics Ltd., a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application No. 16/083,131.